Kohjin Bio Co., Ltd. (TYO:177A)
Japan · Delayed Price · Currency is JPY 845.00
-2.00 (-0.24%)
Aug 27, 2026, 3:30 PM JST
Kohjin Bio Financials Overview
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
| Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Revenue Revenue Growth | 4,694 | 4,939 | 5,206 | 4,770 | 4,742 | 3,947 |
Revenue Growth | -9.45% | -5.13% | 9.14% | 0.59% | 20.14% | 25.81% |
Gross Profit Gross Profit Growth | 1,674 | 1,857 | 2,365 | 1,881 | 2,454 | 2,040 |
Operating Income Operating Income Growth | 157 | 342 | 991 | 597 | 1,268 | 971 |
Net Income Net Income Growth | 128 | 251 | 794 | 384 | 829 | 587 |
Earnings Per Share EPS Growth | 25.04 | 49.10 | 157.41 | 92.20 | 199.04 | 173.30 |
EPS Growth | -82.07% | -68.81% | 70.74% | -53.68% | 14.85% | - |
| Fiscal Year | FY 2026 | FY 2025 | FY 2024 |
|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 |
Cell Processing Business Cell Processing Business Growth | 974.78 | 1,155 | 1,209 |
Microbial Business Microbial Business Growth | 1,425 | 1,782 | 1,656 |
Tissue Culture Business Tissue Culture Business Growth | 2,540 | 2,269 | 1,904 |
Total Total Growth | 4,939 | 5,206 | 4,770 |
| Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Cash & Investments Cash & Investments Growth | 2,381 | 2,486 | 3,149 | 1,726 | 1,462 | 1,734 |
Total Debt Total Debt Growth | 1,837 | 2,190 | 2,386 | 2,469 | 2,098 | 2,227 |
Net Cash (Debt) Net Cash Growth | 544 | 296 | 763 | -743 | -636 | -493 |
Net Cash Growth | -51.03% | -61.21% | - | - | - | - |
Net Cash Per Share Net Cash Per Share Growth | 106.42 | 57.91 | 151.27 | -178.39 | -152.70 | -145.55 |
| Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Cash Flow Operating Cash Flow Growth | - | 698 | 915 | 823 | - | - |
Capital Expenditures CapEx Growth | - | -970 | -862 | -562 | - | - |
Free Cash Flow Free Cash Flow Growth | - | -272 | 53 | 261 | - | - |
Free Cash Flow Growth | - | - | -79.69% | - | - | - |
| Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Gross Margin | 35.66% | 37.60% | 45.43% | 39.43% | 51.75% | 51.69% |
Operating Margin | 3.35% | 6.92% | 19.04% | 12.52% | 26.74% | 24.60% |
Pretax Margin | 3.83% | 6.72% | 19.48% | 13.29% | 26.21% | 23.36% |
Profit Margin | 2.73% | 5.08% | 15.25% | 8.05% | 17.48% | 14.87% |
FCF Margin | - | -5.51% | 1.02% | 5.47% | - | - |
| Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 27, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 |
Dividend Per Share Dividend Per Share Growth | 10.000 | 10.000 | 24.000 | 14.000 | 19.000 |
Dividend Per Share Growth | 0% | -58.33% | 71.43% | -26.32% | - |
Dividend Yield | 1.17% | 0.83% | 1.38% | - | - |
| Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 27, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
PE Ratio | 33.82 | 24.64 | 11.27 | - | - | - |
Forward PE | - | 13.32 | 13.32 | - | - | - |
P/FCF Ratio | - | - | 168.78 | - | - | - |
PS Ratio | 0.92 | 1.25 | 1.72 | - | - | - |